(Q44001924)

28 November 2017

Additive gastrointestinal effects with concomitant use of olestra and orlistat (English)

1 reference

28 November 2017

5

1 reference

28 November 2017

Amy M Heck

1

1 reference

28 November 2017

Karim Anton Calis

series ordinal

2

1 reference

28 November 2017

Jennifer R McDuffie

series ordinal

3

1 reference

28 November 2017

Suzanne E Carobene

series ordinal

4

1 reference

28 November 2017

language of work or name

English

0 references

publication date

1 June 2002

1 reference

Annals of Pharmacotherapy

28 November 2017

1 reference

28 November 2017

36

1 reference

28 November 2017

6

1 reference

28 November 2017

1003-1005

1 reference

Varying body mass index cutoff points to describe overweight prevalence among U.S. adults: NHANES III (1988 to 1994).

28 November 2017

1 reference

Changes in diet, weight, and serum lipid levels associated with olestra consumption

21 January 2018

1 reference

Review and analysis of the effects of olestra, a dietary fat substitute, on gastrointestinal function and symptoms

21 January 2018

1 reference

Effects of olestra and sorbitol consumption on objective measures of diarrhea: impact of stool viscosity on common gastrointestinal symptoms

21 January 2018

1 reference

Gastrointestinal symptoms following consumption of olestra or regular triglyceride potato chips: a controlled comparison.

21 January 2018

1 reference

Orlistat, a new lipase inhibitor for the management of obesity

21 January 2018

1 reference

A method for estimating the probability of adverse drug reactions

21 January 2018

1 reference

Diabetic ketoacidosis associated with orlistat treatment

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1A353

1 reference

28 November 2017

1 reference